SLU-PP-332: reported timelines in the literature
A research-supply catalogue summary of reported timelines for SLU-PP-332, a pan-ERR agonist studied as an exercise mimetic. All findings are from animal or in vitro studies; no human dosing or medical guidance is provide
SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), also referred to as an exercise mimetic in the literature. It is a pan-ERR agonist; the compound is not a drug approved for any human indication, and all reported timelines derive from preclinical models or in vitro systems. The evidence block does not provide a sequence, molecular formula, or molecular weight for SLU-PP-332, so those identifiers are not stated here. The work centres on the ERR family of orphan nuclear receptors, which regulate mitochondrial metabolism and exercise-responsive transcription [2].
Reported timelines in the literature are not clinical timelines. They are intervals observed in cell-based assays, isolated human myoblasts, or rodent models, and they describe when a measured effect appeared after compound exposure or administration. No human pharmacokinetic or dosing timeline for SLU-PP-332 is provided in the evidence block. The sections below summarise what each study reported, with the model and the measured endpoint named.
Research Studies
SLU-PP-332 and in vitro metabolic stability in human liver S9 fractions
An analytical characterisation study examined SLU-PP-332 and SLU-PP-915 using liquid chromatography–high resolution tandem mass spectrometry (LC-HRMS/MS) and prepared in vitro metabolic transformation products using human liver S9 fractions [1]. The work was motivated by the compounds' potential relevance to sports drug testing, given their classification as exercise mimetics. The reported timeline here is an in vitro incubation timeline: the study describes the generation of metabolic transformation products in a liver-fraction system, not in whole animals or humans. The evidence block does not give specific incubation durations or half-lives, so no numerical timeline can be quoted from this source.
SLU-PP-332 and structure–activity relationships in cell-based functional assays
A comprehensive structure–activity relationship (SAR) analysis of the SLU-PP-332 scaffold integrated chemical synthesis, cell-based functional assays, downstream gene-expression profiling, and additional characterisation [2]. This study aimed to elucidate the structural features governing potency, efficacy, selectivity, and drug-like properties. The reported timelines are those of cell-based assays and gene-expression readouts; the evidence block does not specify the exact time points at which functional or transcriptional changes were measured. The work is in vitro and does not provide human timelines.
SLU-PP-332 and ERR activation in myoblasts from inactive women
A pilot study evaluated ERR targeting in myoblasts isolated from the skeletal muscle of inactive women [3]. Twenty women undergoing hip arthroplasty for coxarthrosis were enrolled and divided into an active group (n = 10) and an inactive group (n = 10) based on self-reported physical activity. The study assessed metabolic and expression changes associated with ERR activation in these primary human myoblast cultures. This is an ex vivo human cell model, not a clinical trial of SLU-PP-332 in people. The evidence block does not report the duration of compound exposure or the time course of the measured metabolic and expression changes.
SLU-PP-332 and in vitro metabolite identification for doping control
A separate analysis identified in vitro metabolites of SLU-PP-332 for doping-control purposes [4]. This reference-only source reports that exercise mimetics mimic physical activity and that the World Anti-Doping Agency prohibits their use in sports. The study describes SLU-PP-332 as a small synthetic ERRα/β/γ agonist. The timeline here is again an in vitro metabolism timeline; the evidence block does not provide specific incubation times or metabolite detection windows.
SLU-PP-332 and pharmacological ERR activation as an exercise mimetic
A systematic review examined pharmacological activation of ERRα/β/γ as an exercise mimetic, with the aim of assessing physiological, molecular, and clinical evidence [5]. This reference-only source notes that physical inactivity contributes to chronic disease and that ERR activation has emerged as a molecular strategy to mimic exercise-induced benefits. The review covers multiple compounds and models; it does not provide a single timeline for SLU-PP-332. No human clinical timeline is reported in the evidence block.
SLU-PP-915 and aerobic exercise capacity in animal models
An orally active ERR agonist, SLU-PP-915, was reported to enhance aerobic exercise capacity in animal models [6]. This reference-only source states that ERRα, ERRβ, and ERRγ regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and the Krebs cycle, and that ERRs are essential for skeletal muscle adaptation to aerobic exercise. The reported timeline is that of an oral dosing study in animals; the evidence block does not specify the duration of dosing or the time to observed changes in exercise capacity. This is not a human study.
SLU-PP-332 and metabolic syndrome in a rodent model
A synthetic ERR agonist, SLU-PP-332, was reported to alleviate metabolic syndrome in a rodent model [7]. This reference-only source describes the development of SLU-PP-332 as an exercise mimetic and its evaluation in a disease model. The timeline is that of an animal study; the evidence block does not provide the dosing duration or the time course of metabolic improvements. No human data are reported.
SLU-PP-332 and comparative timelines across models
The table below summarises the model systems and the type of timeline reported for each study. No numerical timelines are given because the evidence block does not supply them.
| Study | Model | Timeline type | Reported interval |
|---|---|---|---|
| [1] | Human liver S9 fractions (in vitro) | Metabolic incubation | Not specified |
| [2] | Cell-based assays and gene-expression profiling | Assay exposure | Not specified |
| [3] | Human myoblasts from inactive women (ex vivo) | Culture exposure | Not specified |
| [4] | In vitro metabolism | Metabolite formation | Not specified |
| [5] | Systematic review (multiple models) | Not applicable | Not specified |
| [6] | Animal (oral dosing) | Dosing duration | Not specified |
| [7] | Rodent metabolic syndrome model | Dosing duration | Not specified |
Across these sources, the reported timelines are limited to in vitro incubation periods, cell-culture exposure durations, and animal dosing intervals. No human clinical timeline for SLU-PP-332 is provided in the evidence block. The compound is described as a research chemical and exercise mimetic probe, not a therapeutic agent with established human timelines.
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential
- [2] Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling
- [3] Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study
- [4] Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes
- [5] [Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications]
- [6] An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
- [7] A Synthetic ERR Agonist Alleviates Metabolic Syndrome